Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer

General Use-results Survey of Alunbrig Tablets "Non-small Cell Lung Cancer"

This study is a survey in Japan of Brigatinib tablets used to treat Japanese people with non-small cell lung cancer. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.

The main aim of the study is to check for side effects related to lung disease from Brigatinib. During the study, participants with non-small cell lung cancer will take Brigatinib tablets according to their clinic's standard practice. The study doctors will check for side effects from Brigatinib for 1 year.

Inclusion criteria Participants with unresectable advanced/recurrent ALK fusion gene-positive non-small cell lung cancer.

Exclusion criteria Participants who has a history of hypersensitivity to any component of birigatinib.